Merck KGaA/€MRK

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Merck KGaA

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Ticker

€MRK
Sector

Primary listing

XETRA

Employees

63,160

Merck KGaA Metrics

BasicAdvanced
€52B
18.22
€6.59
0.61
€2.20
1.83%

What the Analysts think about Merck KGaA

Analyst ratings (Buy, Hold, Sell) for Merck KGaA stock.

Bulls say / Bears say

Merck KGaA raised its full-year organic adjusted EBITDA growth guidance to 4%–8%, up from 2%–7%, underscoring strong performance in its pharmaceuticals and laboratory equipment sectors (Reuters)
In Q1 2025, Merck KGaA reported adjusted EBITDA of €1.54 billion, a 5.6% increase that exceeded analysts’ €1.51 billion forecast, demonstrating resilient profitability (Reuters)
The planned $3.9 billion acquisition of SpringWorks Therapeutics is expected to immediately add revenue, expand Merck’s rare tumor portfolio, and be accretive to earnings per share by 2027 (Reuters)
Merck KGaA issued a more cautious full-year adjusted EBITDA outlook of €5.8 billion–€6.4 billion, down from €6.1 billion–€6.6 billion, citing macroeconomic and foreign-exchange uncertainties (Reuters)
Strong negative currency effects weighed on Q2 performance, with FX headwinds cutting net sales by 4.2% and reducing adjusted EBITDA by 7.2% year-over-year (Merck KGaA Q2 2025 Results)
The acquisition of SpringWorks, while strategic, was framed as necessary to counterbalance pipeline weaknesses after recent experimental drug failures and looming patent cliffs, reflecting underlying R&D risks (FT)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

Merck KGaA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Merck KGaA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €MRK

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Merck KGaA stock | €MRK Share Price | Lightyear